# Anti-amyloid antibodies

Source: https://onco.cc/technologies/da-tech-anti-amyloid-mab/  
OnCo record `da-tech-anti-amyloid-mab` (Technology). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Infused antibodies can lower amyloid in early Alzheimer’s disease. They need monitoring for brain swelling or bleeding on MRI.

## Summary

Lecanemab and donanemab are approved examples in the US for early symptomatic disease after amyloid confirmation. Aducanumab’s Alzheimer’s indication was withdrawn.

## Fields

- Kind: Technology
- Last checked: 2026-09-21
- Tags: dementia-atlas
- Principle: Monoclonal antibodies bind aggregated amyloid and promote clearance, with ARIA as a key risk.

## Sources

- FDA Leqembi: https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval

## Connected records

- fronts: [Anti-amyloid treatment](https://onco.cc/fronts/da-front-anti-amyloid/)
- drugs: [Aducanumab](https://onco.cc/drugs/da-aducanumab/), [Donanemab](https://onco.cc/drugs/da-donanemab/), [Lecanemab](https://onco.cc/drugs/da-lecanemab/)
- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)

---
JSON: https://onco.cc/api/v1/entities/da-tech-anti-amyloid-mab.json